Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Soy Protein on Post- Breast Cancer Surgery Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women diagnosed with breast cancer and scheduled for elective breast cancer surgery (excluding breast biopsy) with axillary lymph node dissection (total and/or sentinel node excision).~* Women who are 21 years or older.~Exclusion Criteria:~* History of significant heart, gastro-intestinal, liver or kidney disease.~* Use of the anticoagulant, warfarin or Coumadin.~* Malabsorption of any kind.~* Diagnosed lactase deficiency.~* Known allergy to any of the tested dietary products.~* Basic daily consumption of soy protein in quantities exceeding 10 g/day.~* Women who are strict vegetarians (i.e. no animal derived dietary sources).~* The use of the following narcotics or adjuvant pharmacotherapy: opioids, anticonvulsants, antidepressants and steroids (except antidepressant use specifically for depression).~* Tumour size (if known) \> 3cm(i.e. size before pre-operative chemotherapy, if administered).~* Locally advanced breast cancer.~* Inflammatory breast cancer.~* Paget's disease of the breast with palpable mass.~* Suspected metastasis.~* Suspected micrometastasis.~* Previous breast surgery of any kind (except needle biopsy).~* The need for bilateral breast surgery.~* The existence of other known cancer, including metastasis, either in the other breast or elsewhere.~* Previous or current endocrine cancer therapy (e.g. selective estrogen receptor modulators, aromatase inhibitor).~* Body mass index (BMI) \> 35.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Soy protein (Type: EXPERIMENTAL): None
- Milk protein (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).